Case Study

Enhanced Paveway™ PLUS Selects Expression Organisms Based On Titer Plus Quality

GettyImages-1154325949-escherichia-coli

Launched in 2007, our core microbial expression system Paveway™ has offered industry leading titers by enabling lead strain selection based on product titer in six weeks from program initiation, that has resulted in the successful expression of 150+ proteins.

Our enhanced Paveway™ PLUS platform operates through an enhanced workflow providing exceptional product titers for a wide range of soluble and insoluble proteins, while maintaining extremely tight control of pre-induction product expression. Fermentations can be run without antibiotic selection pressure while sustaining high plasmid retention, helping avoid regulatory concerns around potential antibiotic resistance and clearance.

This case study highlights the ability of the Paveway PLUS enhanced workflow to detect post translational modifications in partially purified product.

access the Case Study!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma

FUJIFILM Diosynth Biotechnologies